Introduction:
For many years, drug products with reduced dosage frequency have been there. Using technology, the absorption rate for the drug is altered. A drug can either be extended-release or delay-released based on its absorption characteristics. The extended-release drug mostly includes capsules and tablets. In this paper, we shall discuss the extended-release characteristics using Adalat OROS tablets as our samples in this case (Sansom).
Adalat OROS tablets are designed in a way that they are only able to release their medication in a controlled way. The release rate is also done in a pre-determined manner to ensure that the therapeutic level of the blood is maintained.
Technology used to achieve the modified release profile
The Adalat OROS tablets use osmotic pressure as the basis to deliver pharmacotherapy. It is usually done once a day. The drug administration is done using the oral route. So, the release of the drug into the system is determined by the constant water inflow into the blood cells to a reservoir that holds some osmotic agent (Sansom).
The technology employed in the drug is that it is mixed with the agent found in the cell reservoir. For this drug, the form of dosage has a very tiny hole that the dissolved drug is pumped whose rate is determined by the level of osmotic pressure. The entrance of water determines the drugs absorption rate. This rate of release is done within very tight limits. For this reason, the concentration of the blood is maintained in its correct state. The Adalat OROS product is hardly altered by the surrounding. The technology of osmotic pressure in it only relies on water passage into the dosage form (Sansom).
Changing the release rate in this drug is easy since the pharmaceutical only needs to do an alteration of the osmotic agent used and either enlarge or reduce the size of the hole that releases the drug into the cell membranes.
Works Cited:
Sansom, Lloyd. "Oral Extended-Release Products." Australian Prescriber 22.4 (1999): 88-90. Web. 26 Mar. 2016.
